       Document 0625
 DOCN  M9460625
 TI    Fluconazole: pharmacokinetics and indications.
 DT    9404
 AU    Montero-Gei F; Escuela de Ciencias Medicas, Universidad Autonoma de
       Centro; America (UCA), San Jose, Costa Rica.
 SO    Arch Med Res. 1993 Winter;24(4):377-85. Unique Identifier : AIDSLINE
       MED/94162843
 AB    Fluconazole is a new systemic azole antifungal agent, with the imidazole
       group substituted by a triazole, presenting a decrease in lipophilicity,
       soluble in water, weakly bound to plasma proteins, and a wide range of
       formulations. The time to reach steady-state with a once daily dosage is
       approximately 7 days. Distribution of fluconazole is extensive and even
       throughout the tissues, and the drug circulates as a free drug.
       Half-life elimination is approximately 30 h. Indications are given for
       fungal infections in AIDS patients and mycoses.
 DE    Animal  Fluconazole/METABOLISM/*PHARMACOKINETICS/*THERAPEUTIC USE  Human
       Mycoses/*DRUG THERAPY  JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

